BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND FANCF, FAF, 2188, ENSG00000183161, Q9NPI8, MGC126856 AND Treatment
11 results:

  • 1. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and fancf expression in ovarian carcinomas.
    Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
    Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Promoter Hypermethylation of fancf and Susceptibility and Prognosis of Epithelial ovarian cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. RNA interference-mediated fancf silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
    He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
    Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
    Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
    Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Promoter hypermethylation of fancf plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
    Wang Z; Li M; Lu S; Zhang Y; Wang H
    Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CpG methylation of the FHIT, fancf, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
    Dhillon VS; Shahid M; Husain SA
    Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
    Marsit CJ; Liu M; Nelson HH; Posner M; Suzuki M; Kelsey KT
    Oncogene; 2004 Jan; 23(4):1000-4. PubMed ID: 14647419
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
    D'Andrea AD
    Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.